Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study

Oncology
Charalambos KouroussisVassilis Georgoulias

Abstract

Temozolomide, a novel triazene derivative, has shown activity in vitro against lung cancer as well as against brain metastases from a variety of solid tumors including non-small cell lung cancer (NSCLC). The aim of the study was to evaluate the efficacy and safety of temozolomide in pretreated patients with NSCLC. Thirty-one pretreated patients (median age 60 years) with histologically confirmed NSCLC were enrolled. Sixteen (52%) patients had a performance status (ECOG) of 0-1, 12 (39%) had pretreated brain metastases and 28 (90.3%) had received >2 lines of treatment. Temozolomide was administered at a dose of 75 mg/m(2) daily for 21 days every 28 days. A total of 73 chemotherapy cycles were administered. In an intention-to-treat analysis, 2 patients (6.5%; 95% CI: -2.2 to 15.1%) achieved a partial response and 3 (10%) stable disease. The median time to progression was 2.4 months, the median survival time 3.3 months and the 1-year survival rate 22.5%. There was a toxic death due to grade 4 neutropenia. Grade 3 and 4 lymphopenia occurred in 4 (13%) and 2 (6%) patients, respectively. Nonhematological toxicity was mild, consisting of grade 2-3 asthenia (n = 14 patients) and grade 3 diarrhea (n = 1 patient). Prolonged low daily dos...Continue Reading

Citations

Mar 11, 2010·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ryuya YamanakaTetsushi Fukushige
Jul 28, 2009·Apoptosis : an International Journal on Programmed Cell Death·Angeliki KoryllouVassiliki Pletsa
May 2, 2009·Pharmaceutical Research·Mei Lan TanTengku Sifzizul Tengku Muhammad
Dec 1, 2010·Pharmaceutical Research·Nathalie WauthozKarim Amighi
Aug 28, 2013·Indian Journal of Cancer·V NoronhaK Prabhash
Mar 12, 2013·Cancer Chemotherapy and Pharmacology·Adriana RomitiPaolo Marchetti
May 14, 2009·Expert Opinion on Drug Safety·Van Anh TrinhWen-Jen Hwu
Jul 24, 2015·International Journal of Oncology·Rémi RosièreNathalie Wauthoz
Jul 24, 2012·Cancer Treatment Reviews·Zuzana TatarXavier Durando
Jan 30, 2010·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Nathalie WauthozKarim Amighi
Jan 20, 2012·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Carlos Gamboa-VignolleAlejandro Mohar
May 20, 2020·Frontiers in Oncology·Sushma JonnaStephen V Liu
Apr 25, 2019·Journal of Oncology·Cem SimsekSuayib Yalcin
Dec 1, 2020·Critical Reviews in Oncology/hematology·Palma FedeleSaverio Cinieri
Jun 3, 2021·Cancers·Marina Elena CazzanigaMaria Grazia Cerrito

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Sanjiv S AgarwalaElaine M Rankin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D AntonadouN Throuvalas
© 2021 Meta ULC. All rights reserved